Skip to main content

Ocular Pain

2
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Bausch + Lomb
Bausch + LombNJ - Bridgewater
1 program
1
BL1332Phase 2
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
1
BL1332 ophthalmic solutionPhase 11 trial
Active Trials
NCT06978244Active Not Recruiting24Est. Nov 2026
Sylentis
SylentisSpain - Madrid
3 programs
SYL1001PHASE_11 trial
SYL1001PHASE_1_21 trial
SYL1001PHASE_21 trial
Active Trials
NCT01438281Completed30Est. Jun 2012
NCT01776658Completed60
NCT02455999Completed66

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SylentisSYL1001
SylentisSYL1001
Bausch HealthBL1332 ophthalmic solution
SylentisSYL1001

Clinical Trials (4)

Total enrollment: 180 patients across 4 trials

Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain

Start: Jun 201566 patients
Phase 2Completed

Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain

Start: Nov 201260 patients
Phase 1/2Completed
NCT06978244Bausch HealthBL1332 ophthalmic solution

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers

Start: Jul 2025Est. completion: Nov 202624 patients
Phase 1Active Not Recruiting

Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers

Start: Jul 2011Est. completion: Jun 201230 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.